Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • MJFF Research Grant, 2012
    Bay Area Solvent Study - Symptoms (BASS-S)

    Objective/Rationale:             
    Chlorinated solvents are commonly used in a variety of occupations. The solvents trichloroethylene (TCE) and perchloroethylene (PERC) have been associated with an...

  • Improving Levodopa Delivery, 2012
    Enhanced Dopamine Availability, Prolonged Activity and Improved Dyskinesia Profile After Administration of Selectively Deuterated Levodopa

    Objective/Rationale:
    To confirm the found beneficial effects of DP-102 (reduced dyskinetic effects at motoric equieffective doses in comparison to regular levodopa) in a pre-clinical model of Parkinson...

  • LRRK2 Biology LEAPS, 2012
    Combining Mass Spectrometry with Genetic and Pharmacological Approaches to Discover and Validate LRRK2 Substrates

    Objective/Rationale:
    Much recent work has suggested that comprehending the biological properties of an enzyme termed LRRK2 that is mutated in about one percent of all Parkinson’s disease patients...

  • Rapid Response Innovation Awards, 2012
    Development of Small Molecule Hepatocyte Growth Factor Mimetics for the Treatment of Parkinson’s Disease

    Objective/Rationale:
    The goal of this project is to determine the clinical potential of a novel, orally active hepatocyte growth factor mimetic for the prevention and/or treatment of Parkinson’s...

  • MJFF Research Grant, 2012
    Development of Nurr1-RXR Heterodimer Selective Agonists for Parkinson's Disease

    Promising Outcomes of Original Grant:
    We hypothesized that Nurr1 could be targeted indirectly with small molecules through other nuclear hormone receptors, and that such compounds would have...

  • Rapid Response Innovation Awards, 2012
    Attenuation of Neuroinflammation by Brain-targeted Liposomal Methylprednisolone (2B3-201) in Two Pre-clinical Models of Parkinson's Disease

    Objective/Rationale:
    Based on increasing evidence of a chronic, self-sustaining environment of inflammation in the brain – or neuroinflammation – in Parkinson’s disease (PD), the objective of the...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.